Stockreport

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal [Yahoo! Finance]

Evaxion Biotech A/S - American Depositary Share  (EVAX) 
PDF The findings also demonstrate strong and clinically relevant immune responses after EVX-01 administration to metastatic melanoma patients co-treated with anti-PD-1 stan [Read more]